KR102597685B1 - Oral composition comprising parsley extract - Google Patents
Oral composition comprising parsley extract Download PDFInfo
- Publication number
- KR102597685B1 KR102597685B1 KR1020150136507A KR20150136507A KR102597685B1 KR 102597685 B1 KR102597685 B1 KR 102597685B1 KR 1020150136507 A KR1020150136507 A KR 1020150136507A KR 20150136507 A KR20150136507 A KR 20150136507A KR 102597685 B1 KR102597685 B1 KR 102597685B1
- Authority
- KR
- South Korea
- Prior art keywords
- oral composition
- extract
- parsley
- oral
- parsley extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 229940117336 parsley extract Drugs 0.000 title claims abstract description 33
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 210000005239 tubule Anatomy 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 241000208317 Petroselinum Species 0.000 claims description 12
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 12
- 241000194019 Streptococcus mutans Species 0.000 claims description 12
- 235000011197 perejil Nutrition 0.000 claims description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000013588 oral product Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 229940023486 oral product Drugs 0.000 claims description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 3
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical group O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims description 3
- 206010033102 Otosalpingitis Diseases 0.000 claims 4
- 235000001270 Allium sibiricum Nutrition 0.000 claims 2
- 208000006379 syphilis Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 19
- 208000025157 Oral disease Diseases 0.000 abstract description 18
- 208000030194 mouth disease Diseases 0.000 abstract description 18
- 229930014626 natural product Natural products 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 16
- 206010006326 Breath odour Diseases 0.000 description 16
- 239000000606 toothpaste Substances 0.000 description 14
- -1 C 4 alcohols Chemical class 0.000 description 12
- 208000002925 dental caries Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 208000028169 periodontal disease Diseases 0.000 description 9
- 229940034610 toothpaste Drugs 0.000 description 9
- 210000004268 dentin Anatomy 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 241000605894 Porphyromonas Species 0.000 description 6
- 241000194017 Streptococcus Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000024216 Periapical disease Diseases 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 229960004418 trolamine Drugs 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000003298 dental enamel Anatomy 0.000 description 4
- 239000004088 foaming agent Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 208000007565 gingivitis Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 201000001245 periodontitis Diseases 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000011775 sodium fluoride Substances 0.000 description 4
- 235000013024 sodium fluoride Nutrition 0.000 description 4
- 229960000414 sodium fluoride Drugs 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001680 brushing effect Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229960003260 chlorhexidine Drugs 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229940051866 mouthwash Drugs 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 235000019204 saccharin Nutrition 0.000 description 3
- 229940081974 saccharin Drugs 0.000 description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- CSAVDNHVPJNKTC-UHFFFAOYSA-N 5-methyl-2-propan-2-ylcyclohexan-1-ol;5-methyl-2-propan-2-ylphenol;2,2,4-trimethyl-3-oxabicyclo[2.2.2]octane Chemical compound CC(C)C1CCC(C)CC1O.CC(C)C1=CC=C(C)C=C1O.C1CC2CCC1(C)OC2(C)C CSAVDNHVPJNKTC-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000194024 Streptococcus salivarius Species 0.000 description 2
- 241000194023 Streptococcus sanguinis Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 210000003074 dental pulp Anatomy 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229940091249 fluoride supplement Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940029982 garlic powder Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940076522 listerine Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229940084560 sanguinarine Drugs 0.000 description 2
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000007435 Periapical Abscess Diseases 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 235000002770 Petroselinum crispum Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000002595 Radicular cyst Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000010798 Tongue disease Diseases 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000007147 bacterial dysbiosis Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000037123 dental health Effects 0.000 description 1
- 208000019786 dental pulp disease Diseases 0.000 description 1
- 210000002531 dentinal fluid Anatomy 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229940042125 oral ointment Drugs 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000025488 response to cold Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 구강질환 예방 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 파슬리 추출물을 유효성분으로 포함하는 구강용 조성물에 관한 것이다. 본 발명의 파슬리 추출물을 포함하는 구강용 조성물은 구강질환 예방 또는 치료 효과가 우수하며, 천연물 유래의 물질이어서 독성이 없으며, 인체에 적용하여도 부작용을 유발하지 않아 활용도가 높다.The present invention relates to a composition for preventing or treating oral diseases, and more specifically, to an oral composition containing parsley extract as an active ingredient. The oral composition containing the parsley extract of the present invention is excellent in preventing or treating oral diseases, is non-toxic because it is derived from natural products, and does not cause side effects when applied to the human body, making it highly useful.
Description
본 발명은 구강용 조성물에 관한 것으로, 보다 상세하게는 구강질환 예방 또는 치료용 구강용 조성물에 관한 것이다.The present invention relates to an oral composition, and more particularly, to an oral composition for preventing or treating oral diseases.
치아건강의 개념이 사회생활개념으로 변화되면서 구강건강에 관한 관심이 증대되고 있으며 구강질환의 예방과 치료뿐만 아니라, 사회생활을 하는데 있어서 중요한 대인관계의 장애가 되는 구취에 대한 관심도 높아지고 있는 실정이다.As the concept of dental health changes to the concept of social life, interest in oral health is increasing, and interest in bad breath, which is an important obstacle to interpersonal relationships in social life as well as prevention and treatment of oral diseases, is also increasing.
치아조직은 에나멜질, 시멘트질 및 상아질로 구성되어 있다. 외부에 노출되어 있는 치아의 바깥쪽은 에나멜질로 덮여 있고, 치조골 내에 위치하는 치아 뿌리 부분의 바깥쪽은 시멘트질로 덮여 있으며, 이들 내부에 상아질이 존재한다. 상아질에는 상아세관이라는 미세한 관이 상아질 전체에 걸쳐 분포하고 있다. Tooth tissue is composed of enamel, cementum, and dentin. The outside of the tooth exposed to the outside is covered with enamel, and the outside of the tooth root located within the alveolar bone is covered with cementum, and dentin exists inside these. Dentin has microscopic tubes called dentinal tubules distributed throughout the dentin.
치아의 시린이 증상은 노출된 치아의 상아질 부분이 찬 공기나 자극적인 음식물 등에 접촉되었을 때 민감하게 느껴지는 것으로서, 이 증상의 근본적인 원인으로서 치아의 상아질에 존재하는 많은 세관이 외부로 노출되면서 나타난다. 치아의 시린이 증상은 가벼운 증상에서 격렬하고 지속적인 통증까지 다양하게 나타날 수 있다. 또한, 치아는 특성상 재생이 되지 않기 때문에 진통제나 소염제 등의 복용은 시린 현상의 근본적인 해결책이 되지 못하므로 시린이 증상을 완화하기 위한 여러 치료법이 발달하였다.The symptom of sensitive teeth is that the dentin part of the exposed tooth is felt sensitive when it comes in contact with cold air or irritating food. The fundamental cause of this symptom is that many tubules present in the dentin of the tooth are exposed to the outside. Symptoms of sensitive teeth can range from mild symptoms to intense and persistent pain. In addition, because teeth do not regenerate due to their nature, taking painkillers or anti-inflammatory drugs is not a fundamental solution to the phenomenon of sensitive teeth, so various treatments have been developed to alleviate the symptoms of sensitive teeth.
시린이 증상의 치료는 크게 상아세관 밀봉법과 치수신경 탈감작법 두가지가 있다. 상아세관 밀봉법은 노출된 상아세관을 레진 등으로 메우거나 불소 도포 등으로 손실된 법랑질을 다시 회복하는 방법이고, 치수신경 탈감작법은 신경전달이 나트륨 이온과 칼륨 이온의 적정 비율에 의해 조절되는 점을 감안하여 칼륨 이온의 함량을 인위적으로 높여줌으로써 신경이 시린 통증을 느끼지 못하게 하는 치료법이다. 그러나 이러한 전문 치료법의 시술은 치과에 가서 받아야 하는 번거로움이 있어 평소 생활에서 시린이를 치료 또는 예방할 수 있는 시린이를 위한 치약들이 판매되고 있다.There are two main treatments for sensitive teeth: dentinal tubule sealing and pulp nerve desensitization. The dentinal tubule sealing method is a method of restoring lost enamel by filling the exposed dentinal tubules with resin or applying fluoride, while the pulp nerve desensitization method regulates nerve transmission by the appropriate ratio of sodium ions and potassium ions. This is a treatment that prevents nerves from feeling pain by artificially increasing the potassium ion content. However, because this specialized treatment requires the hassle of going to the dentist, toothpastes for sensitive teeth that can treat or prevent sensitive teeth in everyday life are being sold.
이러한 치약들은 상기 2가지 치료방법에 유용한 유효성분을 함유하고 있다. 그러나 이 중 제이인산칼륨 성분 등을 함유하여 치수신경 탈감작 효능이 나타나도록 구성된 치약은 효능이 나타나는 시간이 15일 정도로 길기 때문에 상대적으로 효능이 빨리 나타나는 상아세관 밀봉법에 의한 효능을 갖는 치약이 선호되고 있다. These toothpastes contain active ingredients useful for the above two treatment methods. However, among these, toothpastes that contain potassium phosphate and other ingredients to show the effect of desensitizing the pulpal nerve have a long period of effect, about 15 days, so toothpastes that have the effect of dentinal tubule sealing, which shows the effect relatively quickly, are preferred. there is.
그러나 종래의 상아세관 밀봉효과를 활용한 시린이 전문 치약의 경우 상아세관을 밀봉하기 위하여 유효성분의 미세한 파우더를 함유하게 되는데 통상적으로 칫솔질하는 과정에서 금방 묽게 희석되고, 물로 헹구는 과정에서 대부분 씻겨나가는 바람에 세관이 밀봉되지 못하고 다시 노출하게 되는 문제점이 있었다.However, in the case of Sirin Professional toothpaste, which utilizes the conventional dentinal tubule sealing effect, it contains fine powder of the active ingredient to seal the dentinal tubules, but it is usually quickly diluted during the toothbrushing process and most of it is washed away during the rinsing process with water. There was a problem in that the customs tube was not sealed and was exposed again.
한편, 구취의 원인은 크게 구강 내 원인, 구강 외 원인, 심인적 원인으로 분류되고 그 중 구취 원인의 80~90% 정도를 차지하는 구강 내 원인으로 타액량 감소, 타액 점조도 증가, 수소이온농도 완충능력 감소, 구강 미생물의 양과 활동성 증가 및 혀의 배면에 부착된 설태와 치료되지 않은 치아 우식증과 치주질환과 같은 구강질환 등이 있다.Meanwhile, the causes of bad breath are largely classified into intra-oral causes, extra-oral causes, and psychogenic causes. Among them, oral causes account for about 80-90% of the causes of bad breath, resulting in decreased saliva volume, increased saliva consistency, and hydrogen ion concentration buffering capacity. decrease, increase in the amount and activity of oral microorganisms, tongue coating attached to the back of the tongue, and oral diseases such as untreated dental caries and periodontal disease.
한편, 구강질환 중 치아 우식증과 치주질환은 통증, 저작기능 장애, 치주조직의 파괴 및 구취와 같은 다양한 임상적인 증상을 유발하고 치아상실을 초래하는 주된 요인으로 알려져 있으며 식생활의 변화로 치아 우식의 원인요소는 더 증가하고 있는 실정이다.Meanwhile, among oral diseases, dental caries and periodontal disease are known to cause various clinical symptoms such as pain, impaired chewing function, destruction of periodontal tissue, and bad breath, and are the main factors causing tooth loss. Changes in eating habits are the cause of dental caries. The number of factors is increasing.
치면세균막 내에 서식하면서 치아우식, 치주질환 및 구취를 유발하는 구강병원균 증식을 억제하는 방법으로, 이들 세균들에 대한 살균 및 정균작용을 갖는 항생제를 포함한 다양한 종류의 항균제제가 충치, 치주질환, 치수 및 치근단 감염의 억제 및 치료제로써 개발되어 왔다. It is a method of suppressing the growth of oral pathogens that live in the dental plaque and cause dental caries, periodontal disease, and bad breath. Various types of antibacterial agents, including antibiotics with sterilizing and bacteriostatic effects on these bacteria, are used to treat dental caries, periodontal disease, dental pulp, and other diseases. It has been developed as a treatment and inhibitor of periapical infection.
그런데, 항생제는 우리 몸에 대한 전신적인 부작용과 함께 구강 내 내성균의 출현 및 균교대증을 유발할 수 있기 때문에 장기적인 사용이 곤란하여 단지 치료제로만으로 이용될 수 있다는 단점이 있다. 또한, 항균제인 불소의 경우는 충치예방효과는 뚜렷하지만 아직까지 치주나 치수, 치근단 질환에 대한 효과는 보고된 바가 없다. 그 외에 치약, 양치액, 기타 구강청정제에 사용되고 있는 항균제제로는 생귀나린(sanguinarine), 리스테린(listerine), 퍼록사이드(peroxide), 클로르헥시딘(chlorhexidine) 등이 있는데, 생귀나린은 구강 내에서 세균에 대한 효과가 불분명하고 치주질환 치료효과에 대해서는 더욱 불분명할 뿐만 아니라 가격도 비싸다는 단점이 있고, 리스테린은 알코올이 주성분으로 실제 구강 내에서는 일시적인 효과 내지는 약간의 정균작용이 있으나 장기간 사용시 조직에 대해 위해작용도 나타날 수 있는 단점이 있으며, 최근 미백효과를 위해 첨가되고 있는 퍼록사이드는 세균에 대한 독성 작용이 있으나 동시에 인체조직에도 독성 작용을 나타내어 안전성에 문제가 있을 뿐 아니라 간혹 세균에서 퍼록사이드에 대한 내성균이 출현하기도 한다. 또한 클로르헥시딘은 치태형성억제와 더불어 치주질환 예방 및 치료제로써 현재까지 알려진 제제 중에서 가장 우수한 것으로 알려져 있으나, 조직에 대한 자극, 조직의 착색 및 변성, 특히 자극적인 맛이 강하고 냄새가 심한 부작용을 나타내는 문제점이 있을 뿐 아니라, 그 외도 균교대증이 유발될 수 있고, 발암성이 있어 임신부의 경우 사용이 제한되는 등 치료나 특히 예방의 목적으로 장기간 사용할 수 없는 단점이 있다(Contemporary periodontics [ed. R.J. Genco et al.], p161∼169, p368∼369, p433, C.V. Mosby Company, St. Louis, 1990).However, antibiotics have the disadvantage of being difficult to use long-term and being used only as a treatment because they can cause systemic side effects on our body and the emergence of resistant bacteria in the oral cavity and bacterial turnover. In addition, fluoride, an antibacterial agent, has a clear cavity prevention effect, but its effect on periodontal, dental pulp, or periapical diseases has not yet been reported. In addition, antibacterial agents used in toothpaste, mouthwash, and other mouthwashes include sanguinarine, listerine, peroxide, and chlorhexidine. Sanguinarine is effective against bacteria in the oral cavity. Listerine's main ingredient is alcohol, so it has a temporary effect or a slight bacteriostatic effect in the oral cavity, but it may also have a harmful effect on tissues when used for a long period of time. Peroxide, which has recently been added for whitening effect, has a toxic effect on bacteria, but at the same time, it has a toxic effect on human tissue, so not only is there a safety problem, but sometimes bacteria resistant to peroxide emerge. do. In addition, chlorhexidine is known to be the best among the agents known to date as a preventive and treatment agent for periodontal disease in addition to inhibiting plaque formation. However, it has the side effects of tissue irritation, tissue staining and degeneration, and especially a strong and irritating taste. In addition, there are disadvantages that it cannot be used for long periods of time for treatment or especially prevention purposes, such as it can cause bacterial dysbiosis, and its use in pregnant women is limited due to its carcinogenic properties (Contemporary Periodontics [ed. R.J. Genco et. al.], p161-169, p368-369, p433, C.V. Mosby Company, St. Louis, 1990).
이에 따라, 본 발명자들은 상기와 같은 부작용에 대한 우려가 없으면서도 구강질환, 즉 치아우식, 치주질환, 구취, 시린이 등의 예방 및 개선에 효과가 뛰어난 천연소재를 도출하기 위해 연구를 수행하였다.Accordingly, the present inventors conducted research to derive a natural material that is effective in preventing and improving oral diseases such as dental caries, periodontal disease, bad breath, and sensitive teeth without concerns about the above-mentioned side effects.
이에 본 발명자들은 파슬리 추출물이 구강질환에 우수한 효과를 갖는다는 사실을 확인함으로써 본 발명을 완성하였다.Accordingly, the present inventors completed the present invention by confirming that parsley extract has excellent effects on oral diseases.
따라서, 본 발명의 목적은 파슬리(parsley) 추출물을 유효성분으로 포함하는 구강용 조성물을 제공하는 것이다.Therefore, an object of the present invention is to provide an oral composition containing parsley extract as an active ingredient.
또한, 본 발명의 목적은 상기 조성물을 포함하는 구강용 제품을 제공하는 것이다.Additionally, an object of the present invention is to provide an oral product containing the composition.
상기 과제를 해결하기 위한 하나의 구현예로서, 본 발명은 파슬리(parsley, Petroselinum crispum) 추출물을 유효성분으로 포함하는 구강용 조성물을 제공한다.As an embodiment to solve the above problem, the present invention provides an oral composition containing parsley ( Petroselinum crispum ) extract as an active ingredient.
본 발명에서 상기 조성물은 구강질환 예방 또는 치료용일 수 있다.In the present invention, the composition may be used to prevent or treat oral diseases.
본 발명에서 상기 구강질환은 예를 들어, 이에 한정되는 것은 아니지만, 구취, 시린이, 치아 우식증, 치은염, 치주염, 구강 내 점막 궤양 및 치근단 질환 등을 포함하는 포괄적 개념이다.In the present invention, the oral disease is a comprehensive concept that includes, but is not limited to, bad breath, sensitive teeth, dental caries, gingivitis, periodontitis, oral mucosal ulcer, and periapical disease.
본 발명에서 상기 구강질환은 바람직하게는 시린이일 수 있다.In the present invention, the oral disease may preferably be syrin.
본 명세서에서 사용된 용어, "예방"은 상기 구강용 조성물을 이용하여 질환을 억제 또는 지연시키는 모든 행위를 의미한다. 또한, 본 명세서에서 사용된 용어, "치료"는 상기 구강용 조성물을 이용하여 질환의 증세가 완화되거나 완치되는 모든 행위를 의미한다.As used herein, the term “prevention” refers to all actions that suppress or delay disease using the oral composition. Additionally, the term “treatment” used herein refers to any action in which symptoms of a disease are alleviated or completely cured using the oral composition.
또한, 본 명세서에서 사용된 용어, "완화"는 상기와 같은 구강질환 증상 등이 줄어들거나 누그러지는 것을 의미하며, 개선, 예방, 치료 등을 포함하는 넓은 개념으로 이해될 수 있다.In addition, the term "alleviation" used herein means reducing or alleviating the symptoms of oral diseases such as those described above, and can be understood as a broad concept including improvement, prevention, treatment, etc.
또한, 본 명세서에서 사용된 용어, "개선"은 구강질환 등을 치료하여 증상을 원래의 상태에 가깝도록 회복시키는 것을 의미하는 넓은 개념으로 이해될 수 있다.Additionally, the term “improvement” used in this specification can be understood as a broad concept meaning to restore symptoms to close to their original state by treating oral diseases, etc.
본 명세서에서 사용된 용어, "구취"는 이에 한정되는 것은 아니지만, 후천적인 전신질환에 의해서나 타액중의 단백질, 음식물 찌꺼기 등이 구강 내에서 미생물에 의해 분해되어 생성된 물질이 분해되어 악취를 유발하는 물질을 생성함으로써 발생할 수 있다. 구취를 유발하는 1차 원인인 구강 내 미생물에는 이에 한정되는 것은 아니지만, 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속, 악티노마이세스(Actinomyces) 속, 악티노바실러스(Actinobacillus) 속 등이 있을 수 있다.The term "bad breath" used in this specification is not limited to this, but causes bad odor due to the decomposition of substances produced by microorganisms in the oral cavity due to acquired systemic diseases or when proteins and food residues in saliva are decomposed. It can occur by producing substances that The oral microorganisms that are the primary cause of bad breath are, but are not limited to, Streptococcus genus, Porphyromonas genus, Actinomyces genus, Actinobacillus genus, etc. This can be.
본 명세서에서 사용된 용어, "치아 우식증"은 이에 한정되는 것은 아니지만 구강 내 박테리아에 의해 치아가 손상되어 충치가 생기는 것을 의미한다. 예를 들어, 치아 표면에 생성된 바이오필름인 플라크(plaque)가 원인일 수 있다. 상기 구강 내 박테리아는 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속 등일 수 있다.As used herein, the term “dental caries” is not limited thereto, but means that teeth are damaged by bacteria in the oral cavity, resulting in cavities. For example, plaque, a biofilm formed on the surface of teeth, may be the cause. The oral bacteria may be of the Streptococcus genus, Porphyromonas genus, etc.
본 명세서에서 사용된 용어, "치은염" 및 "치주염"은, 이에 한정되는 것은 아니지만, 치은연하치태내에 존재하는 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속 등의 세균이 적절한 생육조건이 형성되었을 때 치은 부위의 연조직에 감염을 일으켜 치은염 또는 치주염의 치주질환으로 발전하여 잇몸의 염증을 일으키는 구강질환일 수 있다.The terms “gingivitis” and “periodontitis” used in this specification are, but are not limited to, conditions for the growth of bacteria such as Streptococcus and Porphyromonas present in subgingival plaque. When it forms, it can cause infection in the soft tissue of the gingival area and develop into periodontal disease such as gingivitis or periodontitis, which is an oral disease that causes inflammation of the gums.
본 명세서에서 사용된 용어, "구강 내 점막 궤양"은 구내염(stomatitis)이라고도 하며, 이에 한정되는 것은 아니지만 구강 내 세균, 바이러스, 곰팡이 등에 의한 감염으로 인해 구강 내 점막(혜, 잇몸, 입술, 볼 안쪽 등)에 염증이 생기는 질환을 의미하며 상기 세균은 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속 등의 세균일 수 있다.The term "oral mucosal ulcer" used in this specification is also called stomatitis, but is not limited to this, and is not limited to oral mucosa (skin, gums, lips, inner cheek) due to infection by oral bacteria, viruses, fungi, etc. etc.) refers to a disease in which inflammation occurs, and the bacteria may be bacteria of the Streptococcus genus or Porphyromonas genus.
본 명세서에서 사용된 용어, "치근단 질환"은 이에 한정되는 것은 아니지만, 치아의 뿌리 끝을 의미하는 치근단에 염증이 발생한 것을 의미할 수 있다. 치근단 질환으로는 치근단 낭종, 치근단 농양, 치근단 골육종 등이 있으며, 이에 한정되는 것은 아니지만 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속 등의 세균에 의해서 발생할 수 있다.The term “periapical disease” used herein is not limited thereto, but may mean inflammation occurring at the root end of the tooth. Periapical diseases include periapical cysts, periapical abscesses, and periapical osteosarcomas, but are not limited to these and can be caused by bacteria such as Streptococcus and Porphyromonas .
본 명세서에서 사용된 용어, "시린이"는 이에 한정되는 것은 아니지만, 충치나 다른 병적인 원인과 별개로, 외부 자극에 대해 예리하고 일시적이거나 지속적인 통증이 나타나는 모든 현상을 의미한다. 상기 외부 자극은 보통 온도 자극을 의미하며, 대개 차가운 온도 자극에 증상을 호소하는데 뜨거운 온도에 통증이 나타나기도 한다. 이와 같은 온도 자극 외에도 치아의 건조, 외부 물질과의 접촉, 달거나 신 음식을 통한 삼투압 등의 자극에 의해서도 통증이 나타날 수 있다. 이는 치아 전체에 전반적으로 나타나기도 하며, 상악이나 하악, 또는 오른쪽이나 왼쪽 등 특정 부위에 한정되어 나타나기도 하고, 상아질 지각과민증(dentine hyperesthesia), 우식, 치수 염증과 동반하기도 한다.The term "sirini" used herein is not limited thereto, but refers to any phenomenon in which sharp, temporary or persistent pain appears in response to external stimuli, independently of cavities or other pathological causes. The above-mentioned external stimulus usually refers to temperature stimulus, and symptoms are usually reported in response to cold temperature stimulation, but pain may also appear in hot temperature. In addition to temperature stimulation, pain can also occur due to stimulation such as drying of the teeth, contact with external substances, or osmotic pressure from sweet or sour foods. This may appear throughout the entire tooth, or may be limited to specific areas such as the upper or lower jaw, or the right or left, and may be accompanied by dentine hyperesthesia, caries, and pulp inflammation.
이러한 시린이 증상의 원인으로는 상아세관의 입구 노출을 고려할 수 있다.Exposure to the entrance of the dentinal tubules can be considered the cause of these symptoms.
에나멜질 또는 시멘트질이 파괴되어 상아세관의 입구가 외부로 노출되면 상아세관의 세포돌기, 신경 및 상아질액에 의하여 자극이 치수 쪽으로 전달되어 통증을 느낄 수 있다.When enamel or cementum is destroyed and the entrance of the dentinal tubule is exposed to the outside, stimulation is transmitted to the pulp by the cell protrusions, nerves, and dentinal fluid of the dentinal tubule, causing pain.
본 발명의 발명자들은 파슬리 추출물이 치아 표면 및/또는 상아세관 내에 잘 흡착될 수 있는 특성을 가져 시린이 증상의 예방 및 완화에 탁월한 효과가 있음을 확인함으로써 본 발명을 완성하였다.The inventors of the present invention completed the present invention by confirming that parsley extract has a property that allows it to be easily absorbed into the tooth surface and/or dentinal tubules, and thus has an excellent effect in preventing and alleviating the symptoms of sensitive teeth.
본 명세서에서 사용된 용어, "추출물"은 파슬리의 추출 처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.As used herein, the term "extract" refers to an extract obtained by extraction treatment of parsley, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, a crude product or purified product of the extract, or a mixture thereof, etc. This includes the extract itself and all formulations of the extract that can be formed using the extract.
본 발명의 상기 파슬리 추출물은, 상기 파슬리의 천연, 잡종 또는 변종 식물의 다양한 기관으로부터 추출될 수 있고, 예를 들어 파슬리의 종자(씨앗), 뿌리, 지상부, 줄기, 잎, 꽃, 열매의 몸통, 열매의 껍질뿐만 아니라 식물 조직 배양물로부터도 추출이 가능하다.The parsley extract of the present invention can be extracted from various organs of the natural, hybrid, or variant plant of parsley, for example, parsley seeds, roots, aerial parts, stems, leaves, flowers, and fruit body, It can be extracted not only from the fruit peel but also from plant tissue culture.
본 발명의 상기 파슬리 추출물은 바람직하게는 파슬리의 종자 또는 지상부의 추출물일 수 있으며, 더욱 바람직하게는 지상부 추출물일 수 있다. 본 발명에서 상기 지상부는 파슬리의 지상부라면 어느 부위에 한정되는 것은 아니나, 바람직하게는 지상부 전체일 수 있다.The parsley extract of the present invention may preferably be an extract of parsley seeds or aerial parts, and more preferably an extract of the aerial parts. In the present invention, the above-ground part is not limited to any above-ground part of parsley, but may preferably be the entire above-ground part.
본 발명의 상기 파슬리 추출물에 있어서, 상기 파슬리를 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 용매 추출법, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2 종 이상의 방법을 병용하여 수행될 수 있고, 바람직하게는 용매 추출법을 이용하여 수행할 수 있다.In the parsley extract of the present invention, the method of extracting the parsley is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include solvent extraction, hot water extraction, ultrasonic extraction, filtration, and reflux extraction, which may be performed alone or in combination of two or more methods, preferably using a solvent. This can be performed using an extraction method.
본 발명에서 상기 파슬리를 추출하는 데에 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물, 증류수, 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올, 아세톤, 에테르, 벤젠, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, n-헥산, 염산, 초산, 포름산, 구연산, 디에틸에테르 및 사이클로헥산으로 이루어진 군 중에서 선택되는 하나 이상의 용매 등을 들 수 있으며, 알코올을 용매로 사용하는 경우에는 바람직하게는 C1 내지 C4의 알코올(메탄올, 에탄올, 프로판올, 부탄올)을 사용할 수 있다. 본 발명에서 상기 파슬리의 추출 용매로 보다 바람직하게는 물 또는 증류수를 사용할 수 있다.The type of extraction solvent used to extract the parsley in the present invention is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water, distilled water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, citric acid, One or more solvents selected from the group consisting of ethyl ether and cyclohexane may be used. When alcohol is used as the solvent, C 1 to C 4 alcohols (methanol, ethanol, propanol, butanol) are preferably used. there is. In the present invention, water or distilled water can be more preferably used as an extraction solvent for the parsley.
본 발명의 구강용 조성물은 스트렙토코커스(streptococcus) 속 또는 포피로모나스(Porphyromonas) 속, 더욱 상세하게는 스트렙토코커스 뮤탄스(streptococcus mutans), 스트렙토코커스 상귀스(streptococcus sanguis), 스트렙토코커스 상귀니스(Streptococcus sanguinis), 스트렙토코커스 살리바리우스 종 써모필스(Streptococcus salivarius subsp. thermophils), 및 포피로모나스 진지발리스(Porphyromonas gingivalis)로 이루어진 군에서 선택된 하나 이상의 세균에 항균 효과가 탁월하여 구강질환의 예방 및 치료에 우수한 효과가 있음을 확인하였다.The oral composition of the present invention is Streptococcus genus or Porphyromonas genus, more specifically Streptococcus mutans , Streptococcus sanguis , Streptococcus sanguis. sanguinis ), Streptococcus salivarius spp. Thermophils ( Streptococcus salivarius) subsp. thermophils ), and Porphyromonas gingivalis It was confirmed that it has an excellent antibacterial effect on one or more bacteria selected from the group consisting of (Gingivalis ) and is effective in preventing and treating oral diseases.
더 바람직하게는 본 발명의 구강용 조성물은 스트렙토코커스 뮤탄스(streptococcus mutans) 또는 포피로모나스 진지발리스(Porphyromonas gingivalis) 세균에 항균 효과가 탁월할 수 있다.More preferably, the oral composition of the present invention may have an excellent antibacterial effect against Streptococcus mutans or Porphyromonas gingivalis bacteria.
본 발명에 있어서, 상기 파슬리(parsley) 추출물은 조성물 총 중량 대비 1 내지 10 중량% 일 수 있으며, 바람직하게는 조성물 총 중량 대비 3 내지 7 중량% 일 수 있고, 더욱 바람직하게는 조성물 총 중량 대비 4 내지 6 중량% 일 수 있다. 상기 파슬리(parsley) 추출물이 조성물 총 중량 대비 1 중량% 미만인 경우 구강질환에 효과가 미비할 수 있으며, 10 중량% 초과인 경우 양치 시 맛 등의 사용감이 좋지 않아 바람직하지 않다.In the present invention, the parsley extract may be 1 to 10% by weight based on the total weight of the composition, preferably 3 to 7% by weight based on the total weight of the composition, and more preferably 4% by weight compared to the total weight of the composition. It may be from 6% by weight. If the parsley extract is less than 1% by weight of the total weight of the composition, the effect on oral diseases may be minimal, and if it is more than 10% by weight, it is undesirable because the feeling of use, such as taste when brushing teeth, is not good.
본 발명의 구강용 조성물은 상기 파슬리 추출물 이외에, 그 제형 및 사용 목적에 따라 통상적으로 성분들로서, 습윤제, 연마제, 약효제, 감미제, pH조정제, 방부제, 결합제, 향료, 기포제 등을 더 포함할 수 있다. In addition to the parsley extract, the oral composition of the present invention may further include ingredients such as wetting agents, abrasives, medicinal agents, sweeteners, pH adjusters, preservatives, binders, flavoring agents, and foaming agents, depending on the formulation and purpose of use. .
습윤제로는 농글리세린, 글리세린, 소르비톨수용액, 비결정성 소르비톨수용액, 폴리에틸렌글리콜류 및 프로필렌글리콜로 이루어진 군중에서 단독 또는 혼합하여 사용하며, 그 사용량은 구강용 조성물 전체 중량 대비 1 내지 70중량% 포함될 수 있다.Wetting agents are used alone or in combination from the group consisting of concentrated glycerin, glycerin, sorbitol aqueous solution, amorphous sorbitol aqueous solution, polyethylene glycol, and propylene glycol, and the amount used may be 1 to 70% by weight based on the total weight of the oral composition. .
연마제로는 침강실리카, 실리카겔, 지르코늄실리케이트, 인산일수소칼슘, 무수인산일수소칼슘, 함수알루미나, 경질탄산칼슘, 중질탄산칼슘, 칼슘피로인산염, 불용성메타인산염 및 알루미늄실리케이트로 이루어진 군중에서 선택된 1종 등을 사용할 수 있다. 이러한 연마제의 사용량은 일반적으로 구강용 조성물 총 중량 대비 1 내지 60 중량%일 수 있다. 또한 소량 사용되는 첨가제로는 통상 사용되는 성분들로서 감미제, pH 조정제, 방부제, 착색제, 결합제가 포함될 수 있다. The abrasive is one selected from the group consisting of precipitated silica, silica gel, zirconium silicate, calcium monohydrogen phosphate, anhydrous calcium monohydrogen phosphate, hydrous alumina, light calcium carbonate, ground calcium carbonate, calcium pyrophosphate, insoluble metaphosphate, and aluminum silicate. etc. can be used. The amount of such abrasive used may generally be 1 to 60% by weight based on the total weight of the oral composition. Additionally, additives used in small amounts may include commonly used ingredients such as sweeteners, pH adjusters, preservatives, colorants, and binders.
약효제는 불화나트륨, 일불소인산나트륨, 불화나트륨, 불화주석, 클로로헥시딘, 알란토인 클로로히드록시알루미네이트, 아미노카프론산, 염화아연, 염산피리독신, 초산토코페롤, 효소류 등을 단독 또는 2종 이상 혼합하여 사용할 수 있다. Medicinal agents include sodium fluoride, sodium monofluorophosphate, sodium fluoride, stannous fluoride, chlorhexidine, allantoin chlorohydroxyaluminate, aminocaproic acid, zinc chloride, pyridoxine hydrochloride, tocopherol acetate, enzymes, etc., singly or in combination. The above can be mixed and used.
결합제로는 카르복시메틸셀룰로오스나트륨, 카보머, 카라기난, 잔탄검, 알지네이트류 등을 사용할 수 있고, 기포제로서 알킬황산나트륨, 라우릴황산나트륨, 자당지방산에스테르, 소르비탄지방산에스테르 등의 음이온 및 비이온 계면 활성제를 단독 또는 2종 이상을 혼합하여 사용할 수 있다. 이러한 결합제의 사용량은 일반적으로 구강용 조성물 총 중량 대비 0.1 내지 3 중량%이며, 바람직하게 0.5 내지 2 중량%일 수 있다.As binders, sodium carboxymethyl cellulose, carbomer, carrageenan, xanthan gum, alginates, etc. can be used, and as foaming agents, anionic and nonionic surfactants such as sodium alkyl sulfate, sodium lauryl sulfate, sucrose fatty acid ester, and sorbitan fatty acid ester can be used. It can be used alone or in combination of two or more types. The amount of this binder used is generally 0.1 to 3% by weight, preferably 0.5 to 2% by weight, based on the total weight of the oral composition.
감미제로는 사카린, 자일리톨, 에리스리톨, 아스파탐 등을 사용할 수 있으며, 이러한 감미제의 사용량은 일반적으로 구강용 조성물 총 중량 대비 0.05 내지 2 중량%일 수 있다.Sweeteners include saccharin, xylitol, erythritol, aspartame, etc., and the amount of such sweeteners used may generally be 0.05 to 2% by weight based on the total weight of the oral composition.
pH조정제로는 인산나트륨, 인산이나트륨, 구연산, 트리에탄올아민 등을 사용할 수 있다.As pH adjusters, sodium phosphate, disodium phosphate, citric acid, triethanolamine, etc. can be used.
방부제로는 안식향산, 메틸파라벤, 프로필파라벤, 안식향산나트륨 등을 사용할 수 있다. 향료로는 페퍼민트 오일, 스피아민트 오일, 멘톨 등을 혼합하여 사용하기도 하며, 기타 첨가제로서 덱스타라나제 등의 효소류를 사용할 수도 있다.Preservatives include benzoic acid, methylparaben, propylparaben, and sodium benzoate. As a fragrance, a mixture of peppermint oil, spearmint oil, and menthol may be used, and enzymes such as dextranase may be used as other additives.
기포제로는 음이온성 계면활성제인 라우릴황산나트륨, 비이온성 계면활성제인 폴리옥시에틸렌폴리옥시프로필렌의 공중합체(폴록사머), 폴리옥시에틸렌경화피마자유, 폴리옥시에틸렌솔비탄 지방산에스테르 등이 사용될 수 있다. 이러한 기포제의 사용량은 일반적으로 구강용 조성물 총 중량 대비 0.5 내지 5 중량%이며, 바람직하게 0.5 내지 3.5 중량%일 수 있다.Foaming agents include sodium lauryl sulfate, an anionic surfactant, copolymers of polyoxyethylene and polyoxypropylene (poloxamer), polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, etc., which are nonionic surfactants. . The amount of such foaming agent used is generally 0.5 to 5% by weight, preferably 0.5 to 3.5% by weight, based on the total weight of the oral composition.
그밖에 잔량의 물을 포함한다.Additionally, it contains a remaining amount of water.
본 발명의 또 다른 구현예에 따르면, 상기 조성물을 포함하는 구강용 제품을 제공한다.According to another embodiment of the present invention, an oral product containing the composition is provided.
파슬리 추출물을 유효성분으로 하는 본 발명에 따른 구강용 조성물은 일반적으로 구강 건강을 위해 제조, 시판되는 제품들에 모두 포함될 수 있는 구강용 조성물로서, 적용되는 구강용 제품에는 제한이 없다. 예를 들어, 상기 구강용 제품으로는 치약, 구강 스프레이, 구강 세정제, 구강용 연고, 구강 청정제, 가글링 제품, 껌 등을 포함하나 이에 한정되지 않는다. 본 발명의 구강용 제품은 액상, 고상, 현탁액, 젤상, 에어로졸 형태일 수 있으나, 이에 한정되는 것은 아니다.The oral composition according to the present invention, which contains parsley extract as an active ingredient, is an oral composition that can be included in all products generally manufactured and sold for oral health, and there is no limitation to the oral products to which it is applied. For example, the oral products include, but are not limited to, toothpaste, oral spray, mouthwash, oral ointment, mouthwash, gargling product, gum, etc. The oral product of the present invention may be in the form of liquid, solid, suspension, gel, or aerosol, but is not limited thereto.
본 발명의 파슬리 추출물을 포함하는 구강용 조성물은 구강질환 예방 또는 치료 효과가 우수하다.The oral composition containing the parsley extract of the present invention is excellent in preventing or treating oral diseases.
또한, 본 발명의 조성물은 천연물 유래의 물질이어서 독성이 없으며, 인체에 적용하여도 부작용을 유발하지 않아 활용도가 높다.In addition, the composition of the present invention is non-toxic because it is derived from natural products, and does not cause side effects when applied to the human body, making it highly usable.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, to aid understanding of the present invention, it will be described in detail through examples. However, the embodiments according to the present invention may be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
재료 준비Ingredients Preparation
파슬리 추출물의 제조Preparation of parsley extract
파슬리 지상부 약 100g을 분쇄한 후 200mL의 증류수를 가하여 실온에서 1회 추출한 후 여과하여 물 추출물을 얻었다.After pulverizing about 100 g of the aerial part of parsley, 200 mL of distilled water was added, extracted once at room temperature, and then filtered to obtain a water extract.
<< 실험예Experiment example 1> 1>
시린이Sirin 현상 억제 정도 비교 Comparison of phenomenon suppression levels
시린이 억제정도를 비교하기 위하여, 우선 치약을 제조하기 위해 하기 표 1과 같이 일반적으로 사용될 수 있는 카르복시메틸셀룰로오스나트륨, 라우릴황산나트륨, 글리세린(농글리세린(98%)), 소르비톨 수용액(70%), 실리카류(침강 실리카), 잔탄검, 불화나트륨, 향료, 사카린, 구연산, 트리에탄올아민(Triethanol amine(TEA)) 등을 사용하여 대조군 치약을 만들었고, 여기에 파슬리 추출물이 5 중량% 함유된 실험군 치약을 제조하였다.In order to compare the degree of suppression of toothpaste, sodium carboxymethyl cellulose, sodium lauryl sulfate, glycerin (concentrated glycerin (98%)), and sorbitol aqueous solution (70%), which can be commonly used to manufacture toothpaste, are shown in Table 1 below. A control toothpaste was made using silica (precipitated silica), xanthan gum, sodium fluoride, flavoring, saccharin, citric acid, and triethanol amine (TEA), and an experimental group toothpaste containing 5% by weight of parsley extract. was manufactured.
상기에서 제조한 조성물들의 시린이 현상 억제 정도를 비교 측정하였다. 즉, 지각과민치아를 가진 사람으로 이 실험에 참여하기를 동의한 지원자 40명을 연구대상으로 하였으며, 총 연구대상 치아는 80개이다. 또한, 지원자 중 남자가 20명, 여자가 20명이었고, 연령은 20세 내지 50세였다. 연구 대상자들은 치약 내용물을 알지 못하도록 하였고, 총 시험기간은 2주로 하였다. The degree of inhibition of the cold noise phenomenon of the compositions prepared above was compared and measured. In other words, the subjects of the study were 40 volunteers with hyperesthesia teeth who agreed to participate in this experiment, and the total number of teeth subject to the study was 80. Additionally, among the applicants, there were 20 men and 20 women, and their ages ranged from 20 to 50 years old. The study subjects were blinded to the contents of the toothpaste, and the total test period was 2 weeks.
온도자극을 가한 후 환자의 반응을 측정하는 방법으로 시험을 실시하였다. 시험을 실시하기 전에 미리 각 지원자의 지각과민 치아의 과민부위를 체크하였고, 치아의 시린부위에 약 5℃의 차가운 물을 스포이드로 떨어뜨려 평점을 한 후 2주간 각각의 조성물을 1일 3회 사용하게 하고, 2주가 지나 다시 약 5℃의 차가운 물을 스포이드로 떨어뜨려 평점을 하였다. 자극 후 환자의 반응 평점 기준은 다음과 같이 설정하였다. (0점: 아무런 불편감이 없다., 1점: 약간 불편하거나 시리다., 3점: 아프다.). 통계처리는 실험실시 전과 2주 후의 자극 점수를 paired student-t test로 검정하였다.The test was conducted by measuring the patient's response after applying a temperature stimulus. Before conducting the test, the hypersensitivity area of each applicant's hypersensitive teeth was checked in advance, and cold water at about 5°C was dropped with a dropper on the sensitive area of the tooth to give a rating, and each composition was used three times a day for two weeks. After 2 weeks, cold water at about 5°C was added again using a dropper and the score was evaluated. The patient's response rating criteria after stimulation were set as follows. (0 points: no discomfort, 1 point: slightly uncomfortable or sore, 3 points: painful). For statistical processing, the stimulation scores before and 2 weeks after the laboratory test were tested using a paired student-t test.
2주 후의 온도자극에 대한 반응점수는 다음 표 2와 같다.The response scores to temperature stimulation after 2 weeks are shown in Table 2 below.
<< 실험예Experiment example 2> 2>
구취 제거 효과 실험Bad breath removal effect experiment
구취제거 정도를 비교하기 위하여 상기 표 1과 같은 구성으로 대조군 및 실험군 치약을 제조하였다.To compare the degree of bad breath removal, control and experimental group toothpastes were prepared with the same composition as Table 1 above.
치아우식증이 없는 남녀 50명을 선정하여 대상 음료에 대하여 교차 반복 실험(Cross-over test)을 실시하였다. 시판하는 마늘분을 물에 분산시켜 24시간 방치한 후 희석하여 할리미터(Halimeter) 측정값이 700ppb 이상이 되도록 하여, 상기 희석액을 구취 유발원으로 사용하였다. 마늘분 희석액 15ml로 30초간 가글을 한 후 1분 뒤에 할리미터로 구취정도를 측정한 후, 대조군, 실험군 치약을 사용하여 30초~1분간 양치질하였다. 양치질 수 1분, 5분, 30분 경과 후 할리미터로 구취정도를 측정하여 구취억제의 지속여부를 측정하였다. 그 결과는 하기 표 3과 같다.Fifty men and women without dental caries were selected and a cross-over test was conducted on the target drinks. Commercially available garlic powder was dispersed in water and left for 24 hours, then diluted to obtain a Halimeter measurement value of 700 ppb or higher, and the diluted solution was used as a bad breath inducer. After gargling with 15ml of garlic powder dilution for 30 seconds, the level of bad breath was measured with a halimeter 1 minute later, and then brushing the teeth using control and experimental group toothpaste for 30 seconds to 1 minute. After 1 minute, 5 minutes, and 30 minutes of brushing teeth, the degree of bad breath was measured with a halimeter to determine whether the suppression of bad breath lasted. The results are shown in Table 3 below.
<< 실험예Experiment example 3> 3>
항균 효과 실험Antibacterial effect experiment
치아우식과 치주질환 대표유발 세균인, 그람양성균 스트렙토코커스 뮤탄스(Streptococcus mutans)와 그람음성균인 포피로모나스 진지발리스(Porphyromonas gingivalis)를 이용하여 균주를 억제하는 효과가 있는지 페이퍼 디스크 검사법을 사용하여 항균력 테스트를 실시하였다. 상기 각 세균들은 하기 표 4의 최적 배양조건에서 활성을 키운 후, 각 균의 최적배지에서 4~6시간 정도 배양하여 배양액의 탁도를 Macfarland turbidity No. 0.5 (1.5x108)가 되도록 맞춘 후, 0.1ml를 골고루 도말하였다. 멸균한 페이퍼 디스크(Whatman no.5 paper, 8mm diameter)에 파슬리 추출물을 10mg/disc 농도로 접종하여 1시간 동안 흡수건조시킨 뒤 사용하였다. 상기의 각 세균의 최적온도에서 24-48시간 배양 후 생육저지환의 크기(직경 mm)를 측정하였다.A paper disk test was used to determine the effectiveness of inhibiting strains using the gram-positive bacterium Streptococcus mutans , which is a representative cause of dental caries and periodontal disease, and the gram-negative bacterium Porphyromonas gingivalis . An antibacterial test was conducted. Each of the above bacteria was activated under the optimal culture conditions shown in Table 4 below, and then cultured in the optimal medium for each bacteria for about 4 to 6 hours to adjust the turbidity of the culture medium to Macfarland turbidity No. After adjusting to 0.5 (1.5x10 8 ), 0.1 ml was evenly spread. Parsley extract was inoculated at a concentration of 10 mg/disc on a sterilized paper disk (Whatman no. 5 paper, 8 mm diameter), absorbed and dried for 1 hour, and then used. After culturing for 24-48 hours at the optimal temperature for each of the above bacteria, the size (diameter mm) of growth-inhibiting rings was measured.
그 결과는 하기 표 5에 나타낸 것과 같다.The results are as shown in Table 5 below.
상기에 나타낸 바와 같이 본 발명에 따른 조성물은 구취, 시린이, 치아 우식증, 치은염, 치주염, 구강 내 점막 궤양 및 치근단 질환 등의 구강 질환에 탁월한 효과가 있는 것으로 확인할 수 있었다.As shown above, the composition according to the present invention was confirmed to have an excellent effect on oral diseases such as bad breath, sensitive teeth, dental caries, gingivitis, periodontitis, oral mucosal ulcers, and periapical diseases.
Claims (14)
상기 파슬리(parsley) 추출물은 파슬리에 물, 증류수, 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올, 아세톤, 에테르, 벤젠, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, n-헥산, 염산, 초산, 포름산, 구연산, 디에틸에테르 및 사이클로헥산으로 이루어진 군 중에서 선택되는 하나 이상의 용매를 첨가하여 추출한 용매 추출물인 것을 특징으로 하는 시린이의 예방 또는 치료용 구강용 조성물.According to paragraph 1,
The parsley extract is prepared by mixing parsley with water, distilled water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, citric acid, An oral composition for the prevention or treatment of syphilis, characterized in that it is a solvent extract extracted by adding at least one solvent selected from the group consisting of ethyl ether and cyclohexane.
상기 파슬리(parsley) 추출물은 물 또는 증류수 추출물인 것을 특징으로 하는 시린이의 예방 또는 치료용 구강용 조성물.According to paragraph 1,
An oral composition for preventing or treating syringitis, wherein the parsley extract is a water or distilled water extract.
상기 파슬리 추출물은 차이브의 종자 또는 지상부를 추출하여 수득한 것인 것을 특징으로 하는 시린이의 예방 또는 치료용 구강용 조성물.According to paragraph 1,
An oral composition for the prevention or treatment of syringitis, characterized in that the parsley extract is obtained by extracting the seeds or aerial parts of chives.
상기 파슬리(parsley) 추출물은 조성물 총 중량 대비 1 내지 10 중량%인 것을 특징으로 하는 시린이의 예방 또는 치료용 구강용 조성물.According to paragraph 1,
An oral composition for the prevention or treatment of syphilis, characterized in that the parsley extract is 1 to 10% by weight based on the total weight of the composition.
상기 파슬리(parsley) 추출물은 치아 표면 또는 상아세관 내에 흡착되는 것을 특징으로 하는 시린이의 예방 또는 치료용 구강용 조성물.According to paragraph 1,
The parsley extract is an oral composition for preventing or treating sensitive teeth, characterized in that the parsley extract is adsorbed on the tooth surface or dentinal tubules.
상기 파슬리(parsley) 추출물은 파슬리에 물, 증류수, 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올, 아세톤, 에테르, 벤젠, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, n-헥산, 염산, 초산, 포름산, 구연산, 디에틸에테르 및 사이클로헥산으로 이루어진 군 중에서 선택되는 하나 이상의 용매를 첨가하여 추출한 용매 추출물인 것을 특징으로 하는 스트렙토코커스 뮤탄스 또는 포피로모나스 진지발리스에 대한 항균용 구강용 조성물.According to clause 8,
The parsley extract is prepared by mixing parsley with water, distilled water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, citric acid, An oral composition for antibacterial use against Streptococcus mutans or Porphyromonas gingivalis, characterized in that it is a solvent extract extracted by adding at least one solvent selected from the group consisting of ethyl ether and cyclohexane.
상기 파슬리(parsley) 추출물은 물 또는 증류수 추출물인 것을 특징으로 하는 스트렙토코커스 뮤탄스 또는 포피로모나스 진지발리스에 대한 항균용 구강용 조성물.According to clause 8,
An oral composition for antibacterial use against Streptococcus mutans or Porphyromonas gingivalis, wherein the parsley extract is a water or distilled water extract.
상기 파슬리 추출물은 차이브의 종자 또는 지상부를 추출하여 수득한 것인 것을 특징으로 하는 스트렙토코커스 뮤탄스 또는 포피로모나스 진지발리스에 대한 항균용 구강용 조성물.According to clause 8,
An oral composition for antibacterial use against Streptococcus mutans or Porphyromonas gingivalis, wherein the parsley extract is obtained by extracting the seeds or aerial parts of chives.
상기 파슬리(parsley) 추출물은 조성물 총 중량 대비 1 내지 10 중량%인 것을 특징으로 하는 스트렙토코커스 뮤탄스 또는 포피로모나스 진지발리스에 대한 항균용 구강용 조성물.According to clause 8,
An oral composition for antibacterial use against Streptococcus mutans or Porphyromonas gingivalis, wherein the parsley extract is 1 to 10% by weight based on the total weight of the composition.
상기 파슬리(parsley) 추출물은 치아 표면 또는 상아세관 내에 흡착되는 것을 특징으로 하는 스트렙토코커스 뮤탄스 또는 포피로모나스 진지발리스에 대한 항균용 구강용 조성물.According to clause 8,
The parsley extract is an oral composition for antibacterial use against Streptococcus mutans or Porphyromonas gingivalis, wherein the parsley extract is adsorbed on the tooth surface or dentinal tubules.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150136507A KR102597685B1 (en) | 2015-09-25 | 2015-09-25 | Oral composition comprising parsley extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150136507A KR102597685B1 (en) | 2015-09-25 | 2015-09-25 | Oral composition comprising parsley extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170037232A KR20170037232A (en) | 2017-04-04 |
KR102597685B1 true KR102597685B1 (en) | 2023-11-01 |
Family
ID=58588348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150136507A KR102597685B1 (en) | 2015-09-25 | 2015-09-25 | Oral composition comprising parsley extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102597685B1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5839615A (en) * | 1981-09-03 | 1983-03-08 | Lion Corp | Dentrifrice composition |
ES2134743B1 (en) * | 1998-02-06 | 2000-05-01 | Biocosmetics Sl | COMPOSITION FOR THE TREATMENT OF HALITOSIS. |
KR100507292B1 (en) | 2002-12-13 | 2005-08-09 | 주식회사 태평양 | A compositions containing Anthriscus sylvestris Hoffmann extract or Petroselinum sativum Miller extract for external application having effects of improving skin wrinkle |
-
2015
- 2015-09-25 KR KR1020150136507A patent/KR102597685B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
- Banani R. Chowdhury 외. Herbal toothpaste-A possible remedy for oral cancer. Journal of Natural Products, Vol. 6, 2013, pp. 44-55* |
Also Published As
Publication number | Publication date |
---|---|
KR20170037232A (en) | 2017-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102509579B1 (en) | Oral composition comprising cassava extract | |
KR102597684B1 (en) | Oral composition comprising amaranth extract | |
KR20180081032A (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
KR101881636B1 (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
KR20170103476A (en) | Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract | |
KR102597685B1 (en) | Oral composition comprising parsley extract | |
KR20160061852A (en) | Oral composition containing both metal chelating agent and isopropylmethylphenol | |
KR102379228B1 (en) | Oral composition comprising chives extract | |
KR20170051006A (en) | Oral composition containing both isopropylmethylphenol and oral tissue astringent | |
KR20170037231A (en) | Oral composition comprising purslane extract | |
KR102682447B1 (en) | Oral composition comprising hinokitiol | |
KR20020082308A (en) | Composition for the mouth containing extraction of Euonymus alatus Sieb | |
KR101344803B1 (en) | Oral care composition comprising extract of machilus thunbergii and sequestering agent | |
KR102548925B1 (en) | Composition for prevention or treatment of oral disease comprising Scopoletin | |
KR100665891B1 (en) | Oral hygiene compositions containing hydroxytyrosol | |
KR20170103482A (en) | Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract | |
KR20170103494A (en) | Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract | |
KR101818211B1 (en) | Composition for prevention or treatment of oral disease comprising Arctill fructus Extract | |
KR102562829B1 (en) | Composition for prevention or treatment of oral disease comprising Alpinia officinarum Extract | |
KR102562830B1 (en) | Composition for prevention or treatment of oral disease comprising Kochiae Fructus Extract | |
KR20240078208A (en) | Composition for teeth whitening and antibacterial for oral microorganisms comprising apple extract | |
KR20170142975A (en) | Composition for prevention or treatment of oral disease comprising Leonurus sibiricus extract | |
KR100860601B1 (en) | Composition for oral care | |
KR20170120404A (en) | Composition for prevention or treatment of oral disease comprising 2-methoxycinnamaldehyde | |
KR20170118984A (en) | Composition for prevention or treatment of oral disease comprising Leonurus sibiricus extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |